Evidence map›Paper›PMID 26509030›Full record

ArticleClinical case reports2015

The value of in vitro studies in a case of neonatal diabetes with a novel Kir6.2-W68G mutation.

Susan M O'Connell, Peter Proks, Holger Kramer, Katia K Mattis, Gregor Sachse, Caroline Joyce, Jayne A L Houghton, Sian Ellard, Andrew T Hattersley, Frances M Ashcroft and 1 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical case reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. New insights into KNature reviews. Endocrinology · 2020
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Susan M O'ConnellDepartment of Paediatrics and Child Health, Cork University Hospital Cork, Ireland.
Peter ProksDepartment of Physiology Anatomy & Genetics Parks Road, University of Oxford Oxford, OX1 3PT, UK.
Holger KramerDepartment of Physiology Anatomy & Genetics Parks Road, University of Oxford Oxford, OX1 3PT, UK.
Katia K MattisDepartment of Physiology Anatomy & Genetics Parks Road, University of Oxford Oxford, OX1 3PT, UK.
Gregor SachseDepartment of Physiology Anatomy & Genetics Parks Road, University of Oxford Oxford, OX1 3PT, UK.
Caroline JoyceDepartment of Biochemistry, Cork University Hospital Cork, Ireland.
Jayne A L HoughtonInstitute of Biomedical and Clinical Science, University of Exeter Medical School Exeter, EX2 5AD, UK.
Sian EllardInstitute of Biomedical and Clinical Science, University of Exeter Medical School Exeter, EX2 5AD, UK.
Andrew T HattersleyInstitute of Biomedical and Clinical Science, University of Exeter Medical School Exeter, EX2 5AD, UK.
Frances M AshcroftDepartment of Physiology Anatomy & Genetics Parks Road, University of Oxford Oxford, OX1 3PT, UK.
Stephen M P O'RiordanDepartment of Paediatrics and Child Health, Cork University Hospital Cork, Ireland.

Funding

Wellcome Trust 084655Wellcome Trust 098395
6 · The paper itself

Abstract

In infants, especially with novel previously undescribed mutations of the KATP channel causing neonatal diabetes, in vitro studies can be used to both predict the response to sulphonylurea treatment and support a second trial of glibenclamide at higher than standard doses if the expected response is not observed.

Indexed as

Glibenclamidein vitroK-ATP channelneonatal diabetes

Identifiers

PMID26509030
PMCPMC4614663

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.